CAPRICOR THERAPEUTICS, INC. Operating Lease Cost
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Operating Lease Cost of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-14
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $1.51M, a 616.54% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $605.96K, a 188.06% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $619.33K, a 194.42% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $619.33K, a 194.42% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $1.66M, a 97.21% increase from fiscal 2024.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $841.43K, a 6.13% increase from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $792.84K.
- CAPRICOR THERAPEUTICS, INC. operating lease, cost for fiscal 2021 was $129.73K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-14 | $2.11M 10-Q · filed 2026-08-14 | $2.73M derived: sum of 3 quarters · filed 2026-08-14 | $3.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $605.96K 10-Q · filed 2026-05-13 | $1.23M derived: sum of 2 quarters · filed 2026-05-13 | $1.84M derived: sum of 3 quarters · filed 2026-05-13 | $2.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $619.33K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.24M derived: sum of 2 quarters · filed 2026-03-17 | $1.45M derived: sum of 3 quarters · filed 2026-08-14 | $1.66M 10-K · filed 2026-03-17 |
| 2025-09-30 | $619.33K 10-Q · filed 2025-11-10 | $829.69K derived: sum of 2 quarters · filed 2026-08-14 | $1.04M 10-Q · filed 2025-11-10 | $1.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $210.36K 10-Q · filed 2026-08-14 | $420.71K 10-Q · filed 2026-08-14 | $631.07K derived: sum of 3 quarters · filed 2026-08-14 | $841.43K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $210.36K 10-Q · filed 2026-05-13 | $420.71K derived: sum of 2 quarters · filed 2026-05-13 | $631.07K derived: sum of 3 quarters · filed 2026-05-13 | $841.43K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $210.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $420.71K derived: sum of 2 quarters · filed 2026-03-17 | $631.07K derived: sum of 3 quarters · filed 2026-03-17 | $841.43K 10-K · filed 2026-03-17 |
| 2024-09-30 | $210.36K 10-Q · filed 2025-11-10 | $420.71K derived: sum of 2 quarters · filed 2025-11-10 | $631.07K 10-Q · filed 2025-11-10 | $840.66K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $210.36K 10-Q · filed 2025-08-11 | $420.71K 10-Q · filed 2025-08-11 | $630.30K derived: sum of 3 quarters · filed 2025-08-11 | $828.34K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $210.36K 10-Q · filed 2025-05-14 | $419.95K derived: sum of 2 quarters · filed 2025-05-14 | $617.99K derived: sum of 3 quarters · filed 2025-05-14 | $810.59K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $209.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $407.63K derived: sum of 2 quarters · filed 2025-03-26 | $600.24K derived: sum of 3 quarters · filed 2025-03-26 | $792.84K 10-K · filed 2025-03-26 |
| 2023-09-30 | $198.04K 10-Q · filed 2024-11-14 | $390.65K derived: sum of 2 quarters · filed 2024-11-14 | $583.25K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $192.61K 10-Q · filed 2024-08-08 | $385.21K 10-Q · filed 2024-08-08 | ||
| 2021-12-31 | $129.73K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |